53943-88-7
Chemical Structure
Letosteine
- CAS No.: 53943-88-7
- Formula:C10H17NO4S2
- Molecular Weight:279.38
IUPAC Name: 2-(2-((2-ethoxy-2-oxoethyl)thio)ethyl)thiazolidine-4-carboxylic acid
InChIKey: IKOCLISPVJZJEA-UHFFFAOYSA-N
SMILES: CCOC(CSCCC1NC(C(O)=O)CS1)=O
Biological Activity: Letosteine is an orally active, potent and safe expectorant. Letosteine has the effect of scavenging reactive oxygen species (ROS). Letosteine dissolves bronchial mucus and reduces respiratory inflammation symptoms, and restores gas exchanges and natural defense mechanisms in the lung. Letosteine can be used for acute or chronic respiratory diseases (such as bronchopneumopathies) research[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Letosteine | 99.78% | Letosteine is an orally active, potent and safe expectorant. Letosteine has the effect of scavenging reactive oxygen species (ROS). Letosteine dissolves bronchial mucus and reduces respiratory inflammation symptoms, and restores gas exchanges and natural defense mechanisms in the lung. Letosteine can be used for acute or chronic respiratory diseases (such as bronchopneumopathies) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Letosteine (Standard) | Letosteine (Standard) is the analytical standard of Letosteine (HY-107355). This product is intended for research and analytical applications. Letosteine is an orally active, potent and safe expectorant. Letosteine has the effect of scavenging reactive oxygen species (ROS). Letosteine dissolves bronchial mucus and reduces respiratory inflammation symptoms, and restores gas exchanges and natural defense mechanisms in the lung. Letosteine can be used for acute or chronic respiratory diseases (such as bronchopneumopathies) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Jia L. Letosteine. John Wiley & Sons, Ltd, 2014.
- [2]. Macquet V, et al. A new contribution to the treatment of chronic bronchopneumopathies: letosteine. Lille Med. 1979;24(9):735-738. [Content Brief]
- [3]. Zhou Y, et al. Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial. Pharmazie. 2014;69(11):842-849. [Content Brief]
- [4]. Gachon F, et al. Disposition and metabolism of letosteine in rats. Drug Metab Dispos. 1988;16(6):853-857. [Content Brief]
Keywords
